About Cascadian Therapeutics (NASDAQ:CASC)
Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E Ratio-7.39994518559122
Forward P/E Ratio-7.87
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$3.30 per share
Price / Book3.03
Return on Equity-41.50%
Return on Assets-39.04%
Cascadian Therapeutics (NASDAQ:CASC) Frequently Asked Questions
What is Cascadian Therapeutics' stock symbol?
Cascadian Therapeutics trades on the NASDAQ under the ticker symbol "CASC."
How were Cascadian Therapeutics' earnings last quarter?
Cascadian Therapeutics Inc (NASDAQ:CASC) issued its earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.01. During the same period last year, the business posted ($0.09) earnings per share. View Cascadian Therapeutics' Earnings History.
Where is Cascadian Therapeutics' stock going? Where will Cascadian Therapeutics' stock price be in 2018?
6 equities research analysts have issued 1 year price objectives for Cascadian Therapeutics' stock. Their predictions range from $4.00 to $10.00. On average, they expect Cascadian Therapeutics' share price to reach $6.00 in the next year. View Analyst Ratings for Cascadian Therapeutics.
What are Wall Street analysts saying about Cascadian Therapeutics stock?
Here are some recent quotes from research analysts about Cascadian Therapeutics stock:
- 1. According to Zacks Investment Research, "Cascadian Therapeutics, Inc. is a biopharmaceutical company specializing in developing innovative therapeutic product candidates for the treatment of cancer. The company's product candidate is ONT-380, an orally active and selective small molecule HER2 inhibitor which is in preclinical trial stage. Cascadian Therapeutics, Inc., formerly known as Oncothyreon Inc., is headquartered in Seattle, Washington. " (1/9/2018)
- 2. Cantor Fitzgerald analysts commented, "Pooled analysis from Phase Ib trial in HER2+ metastatic breast cancer patients with or without brain metastases demonstrated similarity in PFS between two groups (264P), which is a secondary endpoint in the HER2CLIMB trial." (9/11/2017)
- 3. Cowen Inc analysts commented, "CASC reported 1Q financials and provided a pipeline update." (5/9/2017)
Are investors shorting Cascadian Therapeutics?
Cascadian Therapeutics saw a decrease in short interest in the month of January. As of January 12th, there was short interest totalling 818,899 shares, a decrease of 36.2% from the December 29th total of 1,282,670 shares. Based on an average daily trading volume, of 324,030 shares, the short-interest ratio is currently 2.5 days. Approximately 2.0% of the shares of the company are sold short.
Who are some of Cascadian Therapeutics' key competitors?
Some companies that are related to Cascadian Therapeutics include PTC Therapeutics (PTCT), Amarin (AMRN), Deciphera Pharmaceuticals (DCPH), Alder Biopharmaceuticals (ALDR), Retrophin (RTRX), Dova Pharmaceuticals (DOVA), Flexion Therapeutics (FLXN), GlycoMimetics (GLYC), MacroGenics (MGNX), Sucampo Pharmaceuticals (SCMP), Regenxbio (RGNX), Lexicon Pharmaceuticals (LXRX), Adaptimmune Therapeutics (ADAP), Vanda Pharmaceuticals (VNDA), Jounce Therapeutics (JNCE), Raptor Pharmaceutical (RPTP), Uniqure (QURE) and La Jolla Pharmaceutical (LJPC).
Who are Cascadian Therapeutics' key executives?
Cascadian Therapeutics' management team includes the folowing people:
- Christopher S. Henney Ph.D., Chairman of the Board (Age 76)
- Scott D. Myers, President, Chief Executive Officer, Director (Age 51)
- Julia Marie Eastland, Chief Financial Officer, Vice President - Corporate Development, Secretary (Age 51)
- Gary W. Christianson, Chief Operating Officer (Age 61)
- Scott Peterson Ph.D., Chief Scientific Officer (Age 54)
- Robert W. Azelby, Director (Age 49)
- Gwendolyn A. Fyfe M.D., Independent Director (Age 65)
- Steven P. James, Independent Director (Age 58)
- Ted W. Love M.D., Independent Director (Age 58)
- Daniel Keith Spiegelman, Independent Director (Age 58)
Who owns Cascadian Therapeutics stock?
Cascadian Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.39%), Tekla Capital Management LLC (1.46%), Goldman Sachs Group Inc. (1.31%), Redmile Group LLC (1.28%), Kennedy Capital Management Inc. (0.98%) and Geode Capital Management LLC (0.77%). Company insiders that own Cascadian Therapeutics stock include Christopher S Henney, Gwen A Fyfe, Scott Dunseth Myers and Ted W Love. View Institutional Ownership Trends for Cascadian Therapeutics.
Who sold Cascadian Therapeutics stock? Who is selling Cascadian Therapeutics stock?
Cascadian Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Deutsche Bank AG, P.A.W. Capital Corp, Perkins Capital Management Inc., Rhumbline Advisers and TIAA CREF Investment Management LLC. View Insider Buying and Selling for Cascadian Therapeutics.
Who bought Cascadian Therapeutics stock? Who is buying Cascadian Therapeutics stock?
Cascadian Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Goldman Sachs Group Inc., Kennedy Capital Management Inc., Tekla Capital Management LLC, Essex Investment Management Co. LLC, Unterberg Capital LLC, Alps Advisors Inc. and Millennium Management LLC. Company insiders that have bought Cascadian Therapeutics stock in the last two years include Christopher S Henney, Gwen A Fyfe, Scott Dunseth Myers and Ted W Love. View Insider Buying and Selling for Cascadian Therapeutics.
How do I buy Cascadian Therapeutics stock?
Shares of Cascadian Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cascadian Therapeutics' stock price today?
One share of Cascadian Therapeutics stock can currently be purchased for approximately $9.99.
How big of a company is Cascadian Therapeutics?
Cascadian Therapeutics has a market capitalization of $505.68 million. The biopharmaceutical company earns $-57,700,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis. Cascadian Therapeutics employs 57 workers across the globe.
How can I contact Cascadian Therapeutics?
Cascadian Therapeutics' mailing address is 2601 FOURTH AVENUE SUITE 500, SEATTLE WA, 98121. The biopharmaceutical company can be reached via phone at 206-801-2100 or via email at [email protected]
MarketBeat Community Rating for Cascadian Therapeutics (CASC)MarketBeat's community ratings are surveys of what our community members think about Cascadian Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cascadian Therapeutics (NASDAQ:CASC) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Hold||Hold||Buy|
|Consensus Rating Score: ||2.33||2.40||2.40||2.75|
|Ratings Breakdown: ||1 Sell Rating(s)|
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$6.00||$6.00||$6.00||$7.00|
|Price Target Upside: ||40.36% downside||67.13% upside||67.13% upside||81.82% upside|
Cascadian Therapeutics (NASDAQ:CASC) Consensus Price Target History
Cascadian Therapeutics (NASDAQ:CASC) Analyst Ratings History
(Data available from 2/19/2016 forward)
Cascadian Therapeutics (NASDAQ:CASC) Earnings History and Estimates Chart
Cascadian Therapeutics (NASDAQ CASC) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/25/2013||Q412||$1.09||$0.50||$135.60 million||$123.57 million||View||N/A|
Cascadian Therapeutics (NASDAQ:CASC) Earnings Estimates
Current Year EPS Consensus Estimate: $-1.27 EPS
Next Year EPS Consensus Estimate: $-1.03 EPS
Dividend History for Cascadian Therapeutics (NASDAQ:CASC)
No dividend announcements for this company have been tracked by MarketBeat.com
Cascadian Therapeutics (NASDAQ CASC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.10%
Institutional Ownership Percentage: 84.67%
Cascadian Therapeutics (NASDAQ CASC) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|8/11/2017||Scott Dunseth Myers||Insider||Buy||5,500||$3.74||$20,570.00||49,716|| |
|5/12/2017||Scott Dunseth Myers||Insider||Buy||2,800||$4.00||$11,200.00||44,216|| |
|3/31/2017||Scott Dunseth Myers||Insider||Buy||2,000||$4.11||$8,220.00||41,416|| |
|3/28/2017||Gwen A Fyfe||Director||Buy||1,666||$4.12||$6,863.92||3,332|| |
|3/20/2017||Scott Dunseth Myers||Insider||Buy||1,000||$3.93||$3,930.00||39,416|| |
|2/2/2017||Ted W. Love||Director||Buy||23,000||$4.24||$97,520.00|| |
|1/30/2017||Christopher S Henney||Director||Buy||25,324||$4.11||$104,081.64||50,000|| |
|1/27/2017||Scott Dunseth Myers||Insider||Buy||20,500||$3.76||$77,080.00|| |
|8/17/2016||Scott Dunseth Myers||Insider||Buy||45,000||$1.15||$51,750.00||107,500|| |
|6/28/2016||Scott Dunseth Myers||CEO||Buy||62,500||$0.80||$50,000.00||62,500|| |
|6/1/2015||Diana Hausman||Insider||Buy||5,747||$4.65||$26,723.55|| |
|3/26/2015||Daniel K Spiegelman||Director||Buy||10,000||$1.59||$15,900.00|| |
|3/25/2015||Daniel K Spiegelman||Director||Buy||10,000||$1.63||$16,300.00|| |
|12/17/2014||Bvf Partners L P/Il||Major Shareholder||Buy||378,444||$1.82||$688,768.08|| |
|12/15/2014||Bvf Partners L P/Il||Major Shareholder||Buy||224,949||$1.88||$422,904.12|| |
|9/23/2014||Jay Venkatesan||EVP||Buy||250,000||$2.00||$500,000.00|| |
|7/10/2014||Daniel K Spiegelman||Director||Sell||3,403||$1.72||$5,853.16|| |
|2/20/2014||Daniel K Spiegelman||Director||Sell||12,780||$1.96||$25,048.80|| |
|11/1/2013||Bvf Partners L P/Il||Major Shareholder||Buy||129,000||$1.78||$229,620.00|| |
|8/8/2013||Bvf Partners P/Il||major shareholder||Buy||258,361||$1.65||$426,295.65|| |
|8/1/2013||Bvf Partners L P/Il||Major Shareholder||Buy||338,087||$1.74||$588,271.38|| |
|6/7/2013||Bvf Partners L P/Il||Major Shareholder||Buy||214,467||$1.81||$388,185.27|| |
|12/27/2012||Wendy W Warren||Major Shareholder||Sell||57,943||$64.30||$3,725,734.90|| |
Cascadian Therapeutics (NASDAQ CASC) News Headlines
| Analysts Expect Cascadian Therapeutics Inc (CASC) Will Post Earnings of -$0.29 Per Share|
www.americanbankingnews.com - February 13 at 3:18 PM
|Cascadian Therapeutics Inc (CASC) Receives Consensus Recommendation of "Hold" from Brokerages|
www.americanbankingnews.com - February 10 at 3:24 AM
|Analyzing Cascadian Therapeutics (CASC) and Uniqure (QURE)|
www.americanbankingnews.com - February 9 at 10:12 AM
|Seattle Genetics (SGEN) Commences Tender Offer for Cascadian Therapeutics (CASC)|
www.streetinsider.com - February 9 at 9:14 AM
|ACT NOW: Monteverde & Associates PC Announces An Investigation of Cascadian Therapeutics, Inc. - CASC|
finance.yahoo.com - February 9 at 9:14 AM
|Today’s Research Reports on Trending Tickers: Bellicum Pharmaceuticals and Cascadian Therapeutics|
finance.yahoo.com - February 9 at 9:13 AM
|Today’s Research Reports on Trending Tickers: Cascadian Therapeutics and UnitedHealth Group|
finance.yahoo.com - February 8 at 8:54 AM
|SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Cascadian Therapeutics, Inc. - CASC|
finance.yahoo.com - February 7 at 9:14 AM
|What Seattle Genetics' Surprise Acquisition Means For The Bottom Line - Seeking Alpha|
seekingalpha.com - February 4 at 9:08 AM
|Investors Buy Large Volume of Cascadian Therapeutics Call Options (CASC)|
www.americanbankingnews.com - February 4 at 1:06 AM
|Wired News – Seattle Genetics to Acquire Cascadian Therapeutics|
finance.yahoo.com - February 2 at 9:11 AM
|Cascadian Therapeutics Target of Unusually Large Options Trading (CASC)|
www.americanbankingnews.com - February 2 at 1:16 AM
|Cascadian Therapeutics (CASC) Earnings Growth Limit Rating|
investorplace.com - February 1 at 10:12 AM
|CASCADIAN THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout|
finance.yahoo.com - February 1 at 9:15 AM
|Cascadian Therapeutics Scores Big On Seattle Genetics Acquisition|
finance.yahoo.com - February 1 at 9:15 AM
|Raymond James Financial Lowers Cascadian Therapeutics (CASC) to Market Perform|
www.americanbankingnews.com - January 31 at 5:34 PM
|SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Cascadian Therapeutics, Inc. to Seattle Genetics, Inc. for $10.00 Per Share is Fair to Shareholders|
finance.yahoo.com - January 31 at 4:26 PM
|BRIEF-Seattle Genetics Says If Deal Terminated Under, Cascadian Therapeutics To Pay Fee Of $17 Million|
www.reuters.com - January 31 at 9:25 AM
|Seattle Genetics To Buy Cascadian Therapeutics; Sees Higher Q4 Revenues|
www.nasdaq.com - January 31 at 9:25 AM
|Cascadian's stock rockets to pace premarket gainers after Seattle Genetics buyout deal|
www.marketwatch.com - January 31 at 9:25 AM
|Cascadian (CASC) Alert: Johnson Fistel Investigates Proposed Sale of Cascadian Therapeutics, Inc.; Is $10.00 a Fair Price for Shareholders?|
finance.yahoo.com - January 31 at 9:25 AM
|Cascadian Therapeutics Inc (CASC) Short Interest Down 36.2% in January|
www.americanbankingnews.com - January 29 at 1:20 AM
|Critical Comparison: Cascadian Therapeutics (CASC) versus Regenxbio (RGNX)|
www.americanbankingnews.com - January 28 at 5:18 AM
| Analysts Expect Cascadian Therapeutics Inc (CASC) to Announce -$0.29 Earnings Per Share|
www.americanbankingnews.com - January 27 at 5:20 PM
|Cascadian Therapeutics Inc (CASC) Receives Average Rating of "Hold" from Analysts|
www.americanbankingnews.com - January 16 at 3:38 AM
|Zacks: Brokerages Anticipate Cascadian Therapeutics Inc (CASC) to Post -$0.29 Earnings Per Share|
www.americanbankingnews.com - January 10 at 5:30 PM
|Cascadian Therapeutics (CASC) Rating Lowered to Sell at Zacks Investment Research|
www.americanbankingnews.com - January 9 at 8:12 PM
|Cascadian Therapeutics (CASC) Announces 2018 Outlook|
www.streetinsider.com - January 4 at 5:12 PM
|Cascadian Therapeutics Announces 2018 Outlook and Recent Progress|
finance.yahoo.com - January 4 at 9:36 AM
|Array BioPharma To Present At The Annual J.P. Morgan Healthcare Conference|
www.prnewswire.com - January 2 at 6:29 PM
|BRIEF-Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver From The European Medicines Agency|
www.reuters.com - January 2 at 6:29 PM
|Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency - GlobeNewswire (press release)|
globenewswire.com - January 2 at 9:35 AM
|Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency|
finance.yahoo.com - January 2 at 9:35 AM
|BRIEF-Cascadian Therapeutics Files For Mixed Shelf Of Up To $250 Mln|
www.reuters.com - December 29 at 5:08 PM
|-$0.29 EPS Expected for Cascadian Therapeutics Inc (CASC) This Quarter|
www.americanbankingnews.com - December 25 at 3:26 AM
|Cascadian Therapeutics Inc (CASC) Receives Consensus Rating of "Hold" from Analysts|
www.americanbankingnews.com - December 22 at 3:28 AM
|Cascadian Therapeutics Added to the Nasdaq Biotechnology Index ... - GlobeNewswire (press release)|
globenewswire.com - December 14 at 5:44 PM
|Cascadian Therapeutics subleases big chunk of CTI BioPharma's waterfront HQ|
www.bizjournals.com - December 7 at 5:37 PM
|Prolonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast Cancer|
finance.yahoo.com - December 7 at 5:37 PM
| Brokerages Anticipate Cascadian Therapeutics, Inc. (CASC) Will Post Earnings of -$0.29 Per Share|
www.americanbankingnews.com - December 7 at 11:32 AM
|Cascadian, Potential Catalysts, Recent Highlights, Tucatinib Update|
finance.yahoo.com - November 28 at 8:22 AM
|Cascadian Therapeutics, Inc. (CASC) Receives Consensus Rating of "Hold" from Analysts|
www.americanbankingnews.com - November 27 at 3:46 AM
|Array BioPharma To Present At The 2017 Piper Jaffray Healthcare Conference|
www.prnewswire.com - November 22 at 5:44 PM
|Cascadian Therapeutics: Upside In Other Her2+ Indications - Seeking Alpha|
seekingalpha.com - November 21 at 5:09 PM
|-$0.29 Earnings Per Share Expected for Cascadian Therapeutics, Inc. (CASC) This Quarter|
www.americanbankingnews.com - November 19 at 3:26 PM
|Cascadian Therapeutics, Inc. (CASC) Stock Rating Lowered by Zacks Investment Research|
www.americanbankingnews.com - November 14 at 5:58 PM
|Cascadian Therapeutics, Inc. (CASC) Upgraded to Buy by Zacks Investment Research|
www.americanbankingnews.com - November 13 at 6:30 PM
|Cascadian Therapeutics, Inc. (CASC) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS|
www.americanbankingnews.com - November 9 at 5:44 PM
|Edited Transcript of CASC earnings conference call or presentation 8-Nov-17 9:30pm GMT|
finance.yahoo.com - November 9 at 6:01 AM
|Cascadian Therapeutics Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)|
globenewswire.com - November 8 at 7:53 PM
Cascadian Therapeutics (NASDAQ:CASC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cascadian Therapeutics (NASDAQ:CASC) Income Statement, Balance Sheet and Cash Flow Statement
Cascadian Therapeutics (NASDAQ CASC) Stock Chart for Monday, February, 19, 2018